TÜBINGEN, Germany / BOSTON, USA U. S. September 28, 2023 CureVac N. V. (Nasdaq: CVAC) (CureVac), a global biopharmaceutical company introducing a new generation of messenger ribonucleic acid (mRNA) transformer medicines, today announced that the Düsseldorf Regional Court must There are still proceedings related to 4 intellectual asset rights in CureVac’s infringement lawsuit against BioNTech. A decision on the infringement shall be issued at the latest after the competent patent offices have decided on the validity of the intellectual property rights. The validity of those intellectual asset rights The rights to the assets have been challenged through BioNTech. Under German law, patent infringement and validity proceedings are judged in separate proceedings. Normally, German infringement courts only continue proceedings if the validity of the intellectual assets has been questioned and is also considered to have been challenged. It can therefore be concluded that the Düsseldorf Regional Court found that the four intellectual property rights had been infringed.
Given the peculiarities of German patent law, where infringement and validity of patents are judged by separate procedures, the suspension of proceedings was expected until the validity of intellectual property rights was decided, said Dr. Alexander Zehnder, CEO of CureVac. We are confident in the strength of our intellectual asset portfolio and today’s resolution indicates that intellectual asset rights have been infringed in factor.
The hearing addressed three other intellectual property rights, added to the infringement lawsuit in July 2023. These issues are expected to be resolved in 2024.
In the United States, Pfizer/BioNTech filed a lawsuit against CureVac in July 2022, confirming that Comirnaty® does not infringe 3 CureVac patents. These patents are among ten U. S. patents referenced in CureVac’s counterclaim: 11,135,312; 11 149 278 ; 11 286 492 ; 11 345 920 ; 10 760 070 ; 11 241 493 ; 11 471 525 ; 11 576 966 ; 11,596,686 and 11,667,910
CureVac is represented in the United States through Mark H. Izraelewicz of Marshall, Gerstein.
CureVac (Nasdaq: CVAC) is a global biopharmaceutical corporation in the field of messenger RNA (mRNA) generation, with over 20 years of experience in the progression, optimization and production of this flexible biological molecule. medical purposes. The principle of the patented generation of CureVacs is the use of optimized mRNA as a carrier of knowledge to instruct the human body to produce its own proteins capable of combating a wide diversity of diseases. In July 2020, CureVac entered into a collaboration with GSK to jointly expand new infectious disease prophylactic vaccine products based on CureVac’s second-generation mRNA generation. This collaboration subsequently extended to the progression of second-generation COVID-19 vaccine applicants and changed mRNA vaccine technologies. Building on its proprietary generation, CureVac has built a broad clinical portfolio in the spaces of prophylactic vaccines, anti-cancer treatments, anti-marginal treatments, and rare disease treatments. CureVac N. V. is headquartered in Tübingen, Germany, and has more than 1,100 employees at locations in Germany, the Netherlands, Belgium, Switzerland and the United States. More information can be obtained at www. curevac. com.
CureVac Media & Investor Relations
Dr. Sarah Fakih, Vice President of Corporate Communications and Investor Relations
Phone: 7071 9883-1298
M: 49 160 496949
sarah. fakih@curevac. com
This press release includes statements that constitute forward-looking statements as that term is explained in the Private Securities Litigation Reform Act of 1995, including statements that set forth the opinions, expectations, ideals, plans, objectives, assumptions or assignments of CureVac N. V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc. , CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Nederland B. V. (the Company) in relation to occasions or long-term effects, but with statements that reflect old facts. The examples come with a discussion of the potential effectiveness of the company’s vaccine and remedy applicants, as well as the company’s strategies, financing plans, expansion opportunities and expanding market position. In some cases, you can identify those forward-looking statements by terms such as anticipate, intend, believe, estimate, plan, seek, allocate or expect, possibly, will, or may also simply, be forward-looking, intend or would warrant, the negative of those similar terms or explanations. Forward-looking statements are based on management’s existing ideals and assumptions and data currently available to the Company. However, such forward-looking statements are not guarantees of the Company’s performance and you should not place undue reliance on such statements. Forward-looking statements are subject to a variety of risks, uncertainties and other varying circumstances, including negative global economic situations and continued instability and volatility in global monetary market positions, the ability to discharge financing, the ability to conduct preclinical studies and current and long-term ones. execute clinical trials, timing, expense and uncertainty of regulatory approval, dependence on third parties and collaboration partners, ability to commercialize products, ability to manufacture products. Arrange conceivable adjustments to existing and proposed legislation, regulations and government policies, pressures similar to festival expansion and corporate consolidation. industry, the effects of the COVID-19 pandemic on the Company’s business and operational effects, the ability to manage expansion, dependence on key personnel, dependence on intellectual property coverage, the ability to make certain defense patient and fluctuations in operating effects due to the effect of exchange rates or other factors. Such dangers and uncertainties could cause the statements to be misleading and readers are cautioned not to place undue reliance on such statements. Many of these hazards are beyond the Company’s control and may also cause their actual effects to differ materially from those expected to occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company undertakes no obligation, and in particular disclaims any obligation, to update such statements or to publicly announce the effects of any revisions to such statements to reflect long-term events or developments, unless required by law.
For more information, please refer to the company’s reports and filings with the U. S. Securities and Exchange Commission. UU (SEC). These documents will likely be received by visiting EDGAR at the SEC in www. sec. gov.